CCM
URGN icon

Coldstream Capital Management’s UroGen Pharma URGN Stock Holding History

Coldstream Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29
Closed -$321 – 3240
2025
Q1 		$321 Buy
+29
New +$309 ﹤0.01% 3434

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Coldstream Capital Management's URGN Position: Q2 2025 in Review

Coldstream Capital Management sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 29 shares — an estimated $321 sold.

Coldstream Capital Management first reported a position in URGN in Q1 2025 and held it in 1 quarter. The position peaked at $321 in Q1 2025. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Coldstream Capital Management reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 29 UroGen Pharma shares in Q2 2025, an estimated $321.
  • Coldstream Capital Management first reported a position in UroGen Pharma in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's UroGen Pharma position peaked at $321 in Q1 2025.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.